Genfleet Therapeutics (shanghai) Inc.
Clinical trials sponsored by Genfleet Therapeutics (shanghai) Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for KRAS G12D lung cancer: targeted drug combo enters trial Results expected Apr 2027 (estimated)
- New pill takes on tough pancreatic cancer in major trial Results expected Jun 2027 (estimated)
- New hope for hard-to-treat cancers: targeted combo therapy enters trials Results expected Jul 2027 (estimated)
-
Can a targeted drug combo outsmart a common pancreatic cancer mutation?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding another experimental drug (GFS202A or GFH276) to a targeted therapy (GFH375) works better than GFH375 alone in people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. Participants have already had at…
Phase 2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…
Phase 1/2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New hope for KRAS G12D lung cancer: targeted drug combo enters trial
Disease control Not yet recruitingThis Phase 2 trial tests a new drug called GFH375, alone or combined with other drugs (cetuximab or pemetrexed), as a first treatment for advanced non-small cell lung cancer with a specific KRAS G12D mutation. The study will enroll 90 people who have not had prior treatment. The …
Phase 2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Not yet recruitingThis study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …
Phase 1/2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC